- Home
- IMAB vs ANVS Comparison
IMAB vs ANVS Comparison
Compare IMAB & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ANVS
- Stock Information
- Founded
- IMAB 2014
- ANVS 2008
- Country
- IMAB United States
- ANVS United States
- Employees
- IMAB N/A
- ANVS N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ANVS Health Care
- Exchange
- IMAB Nasdaq
- ANVS Nasdaq
- Market Cap
- IMAB 384.6M
- ANVS 48.3M
- IPO Year
- IMAB 2020
- ANVS 2020
- Fundamental
- Price
- IMAB $3.69
- ANVS $2.32
- Analyst Decision
- IMAB Strong Buy
- ANVS Strong Buy
- Analyst Count
- IMAB 5
- ANVS 4
- Target Price
- IMAB $6.80
- ANVS $17.33
- AVG Volume (30 Days)
- IMAB 1.7M
- ANVS 198.0K
- Earning Date
- IMAB 11-02-2025
- ANVS 11-07-2025
- Dividend Yield
- IMAB N/A
- ANVS N/A
- EPS Growth
- IMAB N/A
- ANVS N/A
- EPS
- IMAB N/A
- ANVS N/A
- Revenue
- IMAB N/A
- ANVS N/A
- Revenue This Year
- IMAB N/A
- ANVS N/A
- Revenue Next Year
- IMAB N/A
- ANVS N/A
- P/E Ratio
- IMAB N/A
- ANVS N/A
- Revenue Growth
- IMAB N/A
- ANVS N/A
- 52 Week Low
- IMAB $0.60
- ANVS $1.11
- 52 Week High
- IMAB $5.90
- ANVS $10.54
- Technical
- Relative Strength Index (RSI)
- IMAB 45.33
- ANVS 43.70
- Support Level
- IMAB $3.20
- ANVS $2.26
- Resistance Level
- IMAB $4.64
- ANVS $2.51
- Average True Range (ATR)
- IMAB 0.41
- ANVS 0.11
- MACD
- IMAB -0.17
- ANVS 0.01
- Stochastic Oscillator
- IMAB 29.88
- ANVS 35.48
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.